紫杉醇注射液联合卡铂治疗卵巢癌对患者免疫功能的影响  

Effect of Paclitaxel Injection Combined with Carboplatin on Immune Function in Patients with Ovarian Cancer

作　　者：喻霞 齐慧丽 张春红 YU Xia;QI Hui-li;ZHANG Chun-hong(Pharmacy Department of Shihezi People's Hospital,Xinjiang Shihezi 832000,China;Department of Gynecology,Shihezi People's Hospital,Xinjiang Shihezi 832000,China;Gynecology of Bazhou People's Hospital,Xinjiang Korla 841000,China)

机构地区：[1]新疆石河子市人民医院药剂科,新疆石河子832000 [2]新疆石河子市人民医院妇科,新疆石河子832000 [3]新疆巴州人民医院妇科,新疆库尔勒841000

出　　处：《中华养生保健》2024年第8期40-44,共5页CHINESE HEALTH CARE

摘　　要：目的探讨紫杉醇注射液联合卡铂治疗卵巢癌对患者免疫功能的影响。方法选取2019年1月—2023年1月新疆石河子市人民医院收治的70例卵巢癌患者作为研究对象,依照治疗方法将患者分为观察组(n=35)与对照组(n=35)。对照组在病理诊断确诊后住院应用卡铂进行治疗,观察组患者病理诊断确诊后住院应用紫杉醇注射液联合卡铂治疗。比较两组患者临床疗效、治疗前后肿瘤标志物血管生成因子表达水平变化,并比较两组患者治疗前后免疫功能变化。结果观察组客观缓解率与疾病控制率明显高于对照组,差异有统计学意义(P<0.05);两组患者治疗前bFGF、VEGF血管生成因子,CA125、Cyfra21-1肿瘤标志物水平比较,差异无统计学意义(P>0.05),治疗后两组患者bFGF、VEGF血管生成因子,CA125、Cyfra21-1肿瘤标志物水平均降低,且观察组低于对照组,差异有统计学意义(P<0.05);治疗前两组患者CD4^(+)、CD3^(+)和CD4^(+)/CD8^(+)数值比较,差异无统计学意义(P>0.05),治疗后两组患者CD4^(+)、CD3^(+)和CD4^(+)/CD8^(+)数值均降低,且观察组高于对照组,差异有统计学意义(P<0.05)。结论紫杉醇注射液联合卡铂治疗卵巢癌疗效显著,能够抑制肿瘤进展,降低肿瘤标志物及血管生成因子表达水平,且能够减轻患者化疗过程中出现的免疫功能损伤,值得临床应用。Objective To investigate the effect of paclitaxel injection combined with carboplatin on immune function in patients with ovarian cancer.Methods 70 patients with ovarian cancer admitted to Shihezi People's Hospital of Xinjiang from January 2019 to January 2023 were retrospectively analyzed,according to treatment methods,the patients were divided into observation group(n=35)and control group(n=35).The control group was treated with carboplatin after confirmed pathological diagnosis and hospitalization,and the observation group was treated with paclitaxel injection combined with carboplatin after confirmed pathological diagnosis and hospitalization.The clinical efficacy,the expression level of tumor marker angiogenesis factor before and after treatment,and the immune function changes of the two groups were compared.Results The objective remission rate and disease control rate of the observation group were signifi cantly higher than those of the control group(P<0.05);There was no signifi cant diff erence in the levels of bFGF,VEGF angiogenic factor,CA125,and Cyfra21-1 tumor markers between the two groups of patients before treatment(P>0.05).After treatment,the levels of bFGF,VEGF angiogenic factor,CA125,and Cyfra21-1 tumor markers decreased in both groups of patients,and the observation group was lower than the control group(P<0.05);Before treatment,there was no signifi cant diff erence in the CD4^(+),CD3^(+),and CD4^(+)/CD8^(+)values between the two groups of patients.After treatment,the CD4^(+),CD3^(+),and CD4^(+)/CD8^(+)values of the two groups of patients decreased,and the observation group was higher than the control group(P<0.05).Conclusion The combination of paclitaxel injection and carboplatin has a signifi cant therapeutic eff ect on ovarian cancer,which can inhibit tumor progression,reduce the expression levels of tumor markers and angiogenic factors,and alleviate immune function damage in patients during chemotherapy.It is worthy of clinical application and promotion.

关 键 词：紫杉醇 卡铂 卵巢癌 免疫功能 临床疗效 肿瘤标志物 

分 类 号：R97[医药卫生—药品]